We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $177M
1-Year Est. Return 91.13%
This Fund
S&P 500
This Quarter Est. Return
-13.93%
1 Year Est. Return
+91.13%
3 Year Est. Return
+230.7%
5 Year Est. Return
+260.67%
10 Year Est. Return
+2,169.5%
AUM
$145M
AUM Growth
-$28.6M
Cap. Flow
-$1.67M
Cap. Flow %
-1.15%
Top 10 Hldgs %
75.3%
Holding
32
New
2
Increased
12
Reduced
8
Closed
7

Top Buys

Rank Stock Value
1
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$5.7M
2
ADMS
Adamas Pharmaceuticals
ADMS
+$2.53M
3
LGND icon
Ligand Pharmaceuticals
LGND
+$2.06M
4
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$1.54M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$1.3M

Top Sells

Rank Stock Value
1
EBS icon
Emergent Biosolutions
EBS
+$2.36M
2
CPIX icon
Cumberland Pharmaceuticals
CPIX
+$2M
3
CHMA
Chiasma, Inc. Common Stock
CHMA
+$1.56M
4
VSTM icon
Verastem
VSTM
+$1.48M
5
MTNB icon
Matinas BioPharma
MTNB
+$1.29M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COLL icon
26
Collegium Pharmaceutical
COLL
$766M
– –
-60,045
Closed -$909K
DMAC icon
27
DiaMedica Therapeutics
DMAC
$364M
– –
-250,000
Closed -$1.14M
EBS icon
28
Emergent Biosolutions
EBS
$318M
– –
-46,800
Closed -$2.36M
VSTM icon
29
Verastem
VSTM
$743M
– –
-41,667
Closed -$1.48M
XENE icon
30
Xenon Pharmaceuticals
XENE
$5.79B
– –
-98,860
Closed -$1M
CHMA
31
DELISTED
Chiasma, Inc. Common Stock
CHMA
– –
-300,000
Closed -$1.56M
1
2

Similar funds

RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
MSA
Marathon Strategic Advisors Pittsburgh, Pennsylvania $177M AUM 66.85% 1-Year Est. Return
HF
Holcombe Financial Atlanta, Georgia $177M AUM 13.35% 1-Year Est. Return
BFAG
Blackston Financial Advisory Group The Villages, Florida $177M AUM 21.44% 1-Year Est. Return
CWP
Clark Wealth Partners O'fallon, Illinois $177M AUM 22.36% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
CMP
Christine Messmer PC Collegeville, Pennsylvania $177M AUM
JESC
J.E. Simmons & Co Dallas, Texas $177M AUM

Stonepine Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Stonepine Capital Management held 32 positions worth $145M, down 16% from $174M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Stonepine Capital Management's Q2 2019 filing shows 2 new, 12 increased, 8 reduced and 7 closed positions. Its largest new stake was Novelion Therapeutics Inc. Common Shares: 491,096 shares worth $383K. The largest sale was Emergent Biosolutions, an estimated $2.36M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.

  • Stonepine Capital Management's largest Q2 2019 buy was Novelion Therapeutics Inc. Common Shares: 491,096 shares worth $383K.
  • Stonepine Capital Management added most to BioDelivery Sciences International, Inc. in Q2 2019, an estimated $5.7M increase.
  • Stonepine Capital Management's biggest Q2 2019 reduction was Cumberland Pharmaceuticals, cutting an estimated $2M.
  • Stonepine Capital Management fully exited Emergent Biosolutions in Q2 2019, selling an estimated $2.36M.
  • Stonepine Capital Management's ten largest holdings make up 75% of its $145M portfolio in Q2 2019.
  • Stonepine Capital Management opened 2 new positions and closed 7 in Q2 2019.
  • Stonepine Capital Management's portfolio value fell 16% quarter-over-quarter to $145M.

Based on Stonepine Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.